Publications by authors named "E Scheijbeler"
Background: CT1812 is a first-in-class, sigma-2 receptor ligand, that prevents and displaces binding of amyloid beta (Aβ) oligomers. Normalization of quantitative electroencephalography (qEEG) markers suggests that CT1812 protects synapses from Aβ oligomer toxicity.
Objectives: Evaluate CT1812 impact on synaptic function using qEEG measurements.
Unlabelled: A novel network version of permutation entropy, the inverted joint permutation entropy (JPE), holds potential as non-invasive biomarker of abnormal excitation-inhibition (E-I) ratio in Alzheimer's disease (AD). In this computational modelling study, we test the hypotheses that this metric, and related measures of signal variability and functional connectivity, are sensitive to altered E-I ratios. The E-I ratio in each neural mass of a whole-brain computational network model was systematically varied.
View Article and Find Full Text PDFBackground And Purpose: To date, the mid- and long-term outcomes of the Collum Femoris Preserving (CFP) stem compared with conventional straight stems are unknown. We aimed to compare physical function at a 5-year follow-up and implant survival at an average of 10-year follow-up in an randomized controlled trial (RCT).
Methods: This is a secondary report of a double-blinded RCT in 2 hospitals.
Article Synopsis
- Conducted a retrospective study of EEG measures in amyloid-positive Alzheimer's patients with MCI or dementia, analyzing data from 148 participants with multiple EEG recordings.
- Found significant changes in EEG patterns over time, particularly increases in theta power and decreases in beta power, with more pronounced effects in the temporal and parieto-occipital brain regions; rates of change differed by disease severity.
- Determined that two-year clinical trials should aim for a minimum sample size that can effectively measure treatment impacts on EEG outcomes, especially given the notable deterioration in MCI patients compared to those with AD dementia.